Claims for Patent: 9,855,371

Summary for Patent: 9,855,371

Title:	Bioresorbable stent
Abstract:	Disclosed herein is a high strength, bioresorbable wall thickness suitable for use in an endoprosthesis such as a stent that is produced by first forming a wall thickness by melt processing or solution processing one or more bioresorbable materials into a tubular shape; drawing the shape from shorter length to an optimum longer length and reducing the diameter from a larger diameter to a smaller diameter to orient the molecular chains of the material; fabricating a stent from the tube formed of the oriented material by cutting a strut pattern in its wall thickness; covering the stent\'s struts with at least one coating to delay degradation of the bioresorbable material; covering the stent\'s struts with one or more controlled release active ingredients to minimize the risk of restenosis or other side effects; crimping the stent onto a balloon catheter assembly; delivering the stent into an anatomical lumen via percutaneous methods to a treatment location; radially expanding the stent from a smaller size to a larger size at the treatment location wherein the stent temporarily supports the anatomical lumen; and removing the catheter from the lumen.
Inventor(s):	Scanlon; John James (Wilmington, DE), Scanlon; Catherine Ann (Wilmington, DE)
Assignee:
Application Number:	14/263,851
Patent Claims:	1. A method of producing a tubular-shaped bioresorbable stent comprising the steps of: providing a solution-processed, flexible first film having a film thickness less than 0.100 millimeters, wherein the first film has major surfaces that are substantially parallel and distinctly greater than the minor surfaces, wherein the first film comprises a single solid bioresorbable material having a weight average molecular weight within the range of greater than 500,000 g/mol to 2,682,000 g/mol or a blend of multiple solid bioresorbable materials wherein at least one material within the blend has a weight average molecular weight within the range of greater than 500,000 g/mol to 2,682,000 g/mol, wrapping the first film around the circumference of a shape-forming device at least two times in a way that forms at least two overlaying separate film thicknesses surrounding at least part of the length of the shape-forming device in a tubular configuration, supporting the inner diameter of the wrapped first film with the shapeforming device substantially maintaining the wrapped film in tubular configuration, heating the supported first film to a temperature above the melting temperature of the material within the first film to form a tubular liquefied material on the outer surface of the shape-forming device, wherein heating the supported first film comprises increasing the temperature of the first film to a temperature between 110 degrees Celsius to 250 degrees Celsius, cooling the liquefied material at a rate within the range of 7 degrees Celsius per minute to 200 degrees Celsius per second on the shapeforming device until the liquefied material is solidified into a greater than 0 percent to 70 percent crystalline material and 30 percent to less than 100 percent amorphous material forming a self-supporting tube having a unified, tube wall thickness, and wherein the tube is suitable for inclusion of a strut pattern. 2. The method of claim 1 further comprises the steps of preparing at least one solution by dissolving one or more solid bioresorbable material(s) within one or more liquid solvent(s), wherein the concentration of the material(s) within the solution is equal to or less than 15 percent of the solution and the remainder of the solution is solvent(s) and/or forming at least one of the solutions into at least one liquid shape that has major surfaces that are substantially parallel and distinctly greater than the minor surfaces and removing the solvent(s) from at least one of the liquid shape(s) thereby converting at least one of the liquid shape(s) into at least one solution-processed, flexible film having major surfaces that are substantially parallel and distinctly greater than the minor surfaces. 3. The method of claim 1 further comprising removing portions of the tube wall thickness forming a strut pattern within the tube wall thickness. 4. The method of claim 1 further comprising removing the tube from the shape-forming device. 5. The method of claim 1 further comprising applying at least one coating that includes at least one active ingredient onto at least some or all the surfaces of the stent. 6. The method of claim 1 further comprising wrapping an additional second different film comprising at least one active ingredient and includes poly (DL-lactide) or a copolymer of DL-lactide and glycolide. 7. The method of claim 1 further comprising forming the film by solvent casting. 8. The method of claim 1 further comprises at least partially producing the stent within a protective environment that minimizes or prevents a reduction of molecular weight of the bioresorbable material(s). 9. The method of claim 1 further comprises sterilizing the stent by electron beam irradiation (e-beam), gamma irradiation, ethylene oxide (EtO), low temperature plasma, steam, dry heat, and/or ultraviolet light. 10. The method of claim 1 further comprises crimping the stent from a larger size to smaller size onto a catheter prior to delivery of the stent into an anatomical lumen and/or expanding the stent from a smaller size to a larger size during deployment of the stent within an anatomical lumen. 11. The method of claim 1, wherein the material comprises one material or a blend of multiple material(s) selected from the group of: amorphous polymers, polymerized lactic acid, hydrolysable polymers and/or copolymers, hydrolysable polyesters and/or copolymers thereof, semi crystalline polymers, homopolymers of L-lactide, poly (L-lactide), poly (glycolide), poly (caprolactone), poly (D-lactide), poly (DL-lactide), copolymers of L-lactide and glycolide, copolymers of L-lactide and D-lactide, copolymers of L-lactide and caprolactone, poly (dioxanone), poly (hydroxyalkanoate), poly (orthoester), poly (4-hydroxybutyrate), poly (anhydride), poly (trimethylene carbonate), poly (butylene succinate), polymers having an ester termination, polymers having an end group comprising free carboxylic acid, polymers having an end group comprising alkyl ester, polymers having an end group comprising decyl ester, polymers having end group comprising docecyl ester, semi-crystalline polymers or copolymers, a polymer containing an acid group, or thermoplastics. 12. The method of claim 1 further comprising strengthening the tube so that the material within the tube has a tensile strength greater than 40 MPa in at least one direction by deforming the tube prior to making a strut pattern in the tube wall thickness, wherein deforming is by first expanding the diameter of the tube and/or elongating the tube when the tube is at a temperature within the range of glass transition temperature (Tg) of the material(s) within the tube and the melting temperature (Tm) of the material(s) within the tube and second by cooling the tube to below the glass transition temperature (Tg) of the material(s) within the tube after expanding and/or elongating the tube to maintain the strengthened tube. 13. The method of claim 1 further comprising crystallizing some or all the material(s) within the tube so that some or all the material(s) within the tube have a crystallinity greater than 0 percent and the remainder of the material(s) within the tube are amorphous by deforming the tube prior to making a strut pattern in the tube wall thickness, wherein deforming is by first expanding the diameter of the tube and/or elongating the tube when the tube is at a temperature within the range of glass transition temperature (Tg) of the material(s) within the tube and the melting temperature (Tm) of the material(s) within the tube and second by cooling the tube to below the glass transition temperature (Tg) of the material(s) within the tube after expanding and/or elongating the tube to maintain the crystallization within the tube. 14. The method of claim 1 further comprising applying one or more coating(s) onto at least some or all the outer surfaces of the stent. 15. The method of claim 1 further comprising using the stent in an end-use application selected for the group of: a device for repair, reconstruction, replacement of hollow organ tissue; a balloon-expandable stent; a bifurcated stent; a biliary stent; a birth control device; a carotid stent; a cell growth platform; a cell transportation device; a cerebral stent; a device for delivering a drug or drugs to an anatomical lumen; a device for local delivery of active ingredients to tubular-shaped lumen or organs for treatment of cancer; a device for reinforcing an anatomical lumen; a device for supporting an anatomical lumen; a device for treatment of cancer within or near an anatomical lumen; a device for treatment of colon or rectal cancer; a device to assist in remodeling of diseased anatomical lumens; a drug delivery device; a drug delivery stent; a gastrointestinal stent; a graft; a iliac stent; a large bronchi stent; a mechanical support device; a modular stent; a nasal stent; a patch; a peripheral vascular stent; a reinforcement device; a renal stent; a repair device; a self-expandable stent; a stent-graft; a superficial femoral artery stent; a scaffold; a tissue engineering application; a trachea stent; a tracheal stent; at treatment; a ureter stent; a urethral stent; a urinary stent; a vascular stent; an anatomical lumen repair or splicing device; an attachment device; an esophageal stent; an implant; an implantable scaffold; an intrauterine device (IUD); an oncology treatment device; and a device for the treatment of cancer; an implantable device or patch; a regenerative medicine device; a coronary vascular stent. 16. The method of claim 1 further comprising incorporating one or more active ingredients into the stent. 17. The method of claim 1 further comprising incorporating one or more active ingredient(s) into the stent, wherein the active ingredients are selected from the group of: 5-Fluorauracil (5-FU); abciximab; ABT-578; actinomcin D; actinomycin; agents affecting extracellular matrix production and organization; agents that bind to the FKBP12 binding protein; agents that binds to the mammalian target of rapamycin (mTOR) and thereby blocks the cell cycle mainly of the smooth muscle cell from the G1 to S phase; agents that block T-cell activation or proliferation; agents that decrease cytokine expression on the cell surface membrane and results in an inhibition of T-cell activation and lower smooth muscle cell selectivity; agents that fight cancer; agents that have ability to stabilize microtubules and thereby inhibit cell division in the G0/G1 and G2/M phases; agents that inhibit platelet aggregation; agents that inhibit smooth muscle cell proliferation; agents that inhibits the calcineurin receptor; agents that interfere with endogenous vasoactive mechanisms; agents that interferes with endogenous vasoactive mechanisms; agents that prevent or reduce blood clotting; agents that prevent or reduce allergic reactions; agents that promote endothelialization; agents that reduce neointimal hyperplasia; agents that reduce the size of tumors; agents that reduce vascular hyperplasia; an inhibitor of mammalian target of rapamycin (mTOR); amorphous drugs; analgesics; anesthetic agents; anti-cancer agents; anticoagulants; anti-inflammatory agents; anti-irritant agents; anti-migratory agents; antimitotic agents; anti-proliferative agent; anti-sense nucleotides and transforming nucleic acids; anti-thrombotic agents; antibiotics; antibodies; antimicrobials; antineoplastic agents; antiproliferative drugs; Ap-17; bacteria; bARKct inhibitors; batistimat; beta-blockers; bevacizumab; bioactive agents; Biolimus A9; bisphosphonates; bleomycin; buffering agents; capecitabine; capox; carboplatin; carboplatin AUC 6; cetuximab; chaperone inhibitors; chemotherapeutic agents; cilostazole; cisplatin; clopidogrel; corticosteroids; crystalline forms of drugs; crystalline drugs; crystalline materials; cyclosporine; cytostatic drugs; dexamethasone; deoxyribonucleic acid (DNA); docetaxel; doxorubicin hydrochloride; drugs; drugs that interfere with cells ability to reproduce; endothelial progenitor cells (EPC); epidermal growth factor inhibitors; epirubicin; erythropoietin (Epo D); estradiol; estrogen; everolimus; everolimus (certican or RAD-001); FKBP-12 binding agents; flunisolide; fluorouracil; folfiri; folfiri-bevacizumab; folfiri-cetuximab; folfox; gefitinib; geldanamycin; gemcitabine; genetic therapeutic agents; genistein; glucocorticosteroids; growth factors and delivery vectors including recombinant micro-organisms and liposomes; halofuginone; hormones; human apolioproteins (e.g. AI, AII, AIM, AIV, AV, etc.); hydrocortisone; hypothemycin; imiquimod (as well as other imidazoquinoline immune response modifiers); immunosuppressive agents; irinotecan; irinotecan hydrochloride; leptomycin B; leucovorin calcium; limus drugs; liprostin; living cells; lomustine (CCNU); macrolide antibiotics including FKBP-12 binding compounds; at influence pH in environment surrounding endoprosthesis; materials that promote improvement in elasticity of anatomical lumen; materials that promote remodeling of anatomical lumen; materials that provide reparative effect on anatomical lumen; materials that slow down aging process of anatomical lumen; methotrexate; mineralocorticoids; mitomycin; mitotic inhibitors; modified DNA; mometasone furoate; mometasone furoate monohydrate; mTOR inhibitors; myolimus; natural materials; nitric oxide; non-genetic therapeutic agents; novolimus; nucleic acids; oxaliplatin; oxaliplatin and capecitabine; paclitaxel; panitumumab; pegylated liposomal doxorubicine; peptides; peroxisome proliferator-activated receptor gamma ligands (PPAR.gamma.); pharmaceutically active agents; pharmaceutically active agents having optimized morphology; pharmaceuticals; phospholamban inhibitors; pimecrolimus; polypeptides; progestin; protease inhibitors; proteasome inhibitors; protein-tyrosine kinase inhibitors; proteins; radiation; rapamcin hydroxyesters; rapamycin; rapamycin derivatives; regorafenib; regoranfenib, resiquimod; Resten-NG; Ridogrel; Serca 2 gene/protein; semi-crystalline drugs; sirolimus; sirolimus salicylate; statins; steroids; tacrolimus; tacrolimus (FK506); taxol, temsirolimus; temsirolimus (CCI-779 or amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methyl-propionic acid); therapeutic agents; topotecan; toxic compounds; trapidil; trastuzumab; vascular cell growth inhibitor; vascular cell growth promoter; vascular endothelial growth factors (e.g. VEGF-2); vasodilating agents; vinorelbine; virus; ziv-afibercept; zotarolimus; or zotarolimus. 18. The method of claim 1, further comprising including at least one additive within the bioresorbable material. 19. The method of claim 1 further comprising wrapping at least one additional film around the shape-forming device prior to liquefying the first film and/or additional film(s) and cooling the first and/or additional film(s), wherein the additional film(s) comprise: a material or a blend of materials having a molecular weight equal to or less than 500,000 g/mol, a material or a blend of materials having a molecular weight equal to or greater than 2,682,000 g/mol, a material or a blend of materials having the same or a different chemical composition than the first film, a material or a blend of materials having the same or a different molecular weight than the first film, a material or a blend of materials having the same or a different degradation rate than the first film where the degradation rate is the rate at which the material(s) lose substantial strength at physiological conditions, a material or a blend of materials having the same or a different resorption rate than the first film where the resorption rate is the rate at which the material(s) lose substantial mass at physiological conditions, a material or blend of materials having the same or a different melting temperature than the first film, a material or blend of materials having the same or a different degree of crystallinity than the first film, a material or blend of materials having the same or one or more different physical properties than the first film where the physical properties minimally include the tensile strength, elastic modulus, and/or elongation-to-break properties. 20. The method of claim 1 further comprising wrapping at least one additional film around the shape-forming device prior to liquefying the first film and/or the additional film(s) and cooling the first film and/or additional films(s), wherein the first film comprises poly (L-lactide) or a copolymer of L-lactide and the additional film(s) comprise one bioresorbable material or a blend of multiple bioresorbable materials selected from the group of: poly (L-lactide) or copolymers of L-lactide having a different molecular weight than the first film; poly (L-lactide) or copolymers of L-lactide having a molecular weight equal to or greater than 2,682,000 g/mol; poly (L-lactide) or copolymers of L-lactide having a molecular weight equal to or less than 500,000 g/mol; poly (glycolide) or copolymers glycolide; poly (caprolactone) or copolymers of caprolactone; poly (D-lactide) or co-polymers of D-lactide; and poly (DL-lactide) or co-polymers of DL-lactide.

Details for Patent 9,855,371

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	REOPRO	abciximab	Injection	103575	12/22/1994		2039-02-26
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2039-02-26
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2039-02-26
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	02/12/2004		2039-02-26
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	03/28/2007		2039-02-26
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2039-02-26